Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daxor Reports 2008 Results
Gains on sales of securities and dividend income were 39.0% of invested capital for the year ended December 31, 2008, compared with up 57.6 for the year 2007.
Gains on sales of securities and dividend income were 39.0% of invested capital for the year ended December 31, 2008, compared with up 57.6 for the year 2007.
For the 12 months ended December 31, 2008, the company reported a net loss attributable to common stockholders of $26.03 million, or $1.49 per share, compared to a
Drug Fair Group and its parent company CDI Group have filed voluntary petitions for reorganization under Chapter 11 of the US Bankruptcy Code in the US Bankruptcy Court
Adventrx’s remaining employees, which will consist of its chief business officer and senior vice president, its general counsel, its senior vice president of operations, its vice president of
XTL Biopharmaceuticals has entered into an asset purchase agreement with Bio-GAL, a private company, for the rights to a use patent on recombinant erythropoietin for the prolongation of
The company reported a net loss of $495,000, or $0.01 per share, for the year ended December 31, 2008, compared to a net loss of $2.11 million, or
Under the terms of the contract, Aesthetic has obtained a one-year exclusive license to market the Lapex 2000 BCS series in Sweden, Norway, Denmark and Finland. Meridian signed
EnCor and SenoRx breast tissue biopsy markers have previously received regulatory clearances from China’s State Food & Drug Administration and from countries within the European Economic Community and
The new project will focus on detailed cell-based studies to further advance the validation of novel oncology target candidates successfully identified by Cenix in screens completed recently for
Dr John has most recently served as head of R&D at Centegen, a biotechnology start-up. She brings 17 years of experience in the manufacture of biologics and the